Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,575,160
  • Shares Outstanding, K 57,435
  • Annual Sales, $ 383,480 K
  • Annual Income, $ -146,370 K
  • EBIT $ -88 M
  • EBITDA $ -52 M
  • 60-Month Beta 0.67
  • Price/Sales 13.82
  • Price/Cash Flow N/A
  • Price/Book 7.79

Options Overview Details

View History
  • Implied Volatility 61.95% (+0.44%)
  • Historical Volatility 38.52%
  • IV Percentile 71%
  • IV Rank 44.21%
  • IV High 92.88% on 04/11/25
  • IV Low 37.45% on 01/22/25
  • Expected Move (DTE 35) 15.43 (12.83%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 204
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 2,482
  • Open Int (30-Day) 2,248
  • Expected Range 104.81 to 135.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.23
  • Number of Estimates 7
  • High Estimate -0.09
  • Low Estimate -0.30
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +42.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.96 +27.97%
on 01/14/26
121.63 -1.14%
on 01/16/26
+6.48 (+5.70%)
since 12/16/25
3-Month
73.16 +64.35%
on 10/28/25
121.63 -1.14%
on 01/16/26
+34.91 (+40.91%)
since 10/16/25
52-Week
73.16 +64.35%
on 10/28/25
163.71 -26.55%
on 01/23/25
-36.27 (-23.17%)
since 01/16/25

Most Recent Stories

More News
Stock Indexes Settle Lower on Tech Weakness

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.07%. March...

MSTR : 173.71 (+1.64%)
GOOGL : 330.00 (-0.84%)
MPC : 175.63 (-1.10%)
GLXY : 34.31 (+7.25%)
RIVN : 16.67 (-2.29%)
ABNB : 130.66 (-1.46%)
COIN : 241.15 (+0.78%)
TGTX : 30.57 (-0.46%)
OXY : 42.70 (-1.09%)
TSLA : 437.50 (-0.24%)
^BTCUSD : 95,468.09 (-0.06%)
SPY : 691.66 (-0.08%)
Stocks Retreat as Big Tech Falters

The S&P 500 Index ($SPX ) (SPY ) today is down -0.96%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.57%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.53%. March E-mini S&P futures...

MSTR : 173.71 (+1.64%)
GOOGL : 330.00 (-0.84%)
MPC : 175.63 (-1.10%)
GLXY : 34.31 (+7.25%)
RIVN : 16.67 (-2.29%)
COIN : 241.15 (+0.78%)
TGTX : 30.57 (-0.46%)
OXY : 42.70 (-1.09%)
TSLA : 437.50 (-0.24%)
^BTCUSD : 95,468.09 (-0.06%)
SPY : 691.66 (-0.08%)
META : 620.25 (-0.09%)
Stocks Pressured by Tech Weakness and Iran Tensions

The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.22%. March E-mini S&P futures...

AMAT : 327.01 (+2.49%)
GOOGL : 330.00 (-0.84%)
MPC : 175.63 (-1.10%)
AVGO : 351.71 (+2.53%)
CVX : 166.26 (+0.06%)
FN : 494.45 (-0.63%)
RIVN : 16.67 (-2.29%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
MSFT : 459.86 (+0.70%)
TGTX : 30.57 (-0.46%)
OXY : 42.70 (-1.09%)
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 120.24 (+5.03%)
Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.24 (+5.03%)
Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 120.24 (+5.03%)
Glaukos: Q3 Earnings Snapshot

Glaukos: Q3 Earnings Snapshot

GKOS : 120.24 (+5.03%)
Glaukos Announces Third Quarter 2025 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 120.24 (+5.03%)
Glaukos Announces FDA Approval of Epioxaâ„¢

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel,...

GKOS : 120.24 (+5.03%)
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced...

GKOS : 120.24 (+5.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an...

See More

Key Turning Points

3rd Resistance Point 130.92
2nd Resistance Point 126.28
1st Resistance Point 123.26
Last Price 120.24
1st Support Level 115.59
2nd Support Level 110.95
3rd Support Level 107.93

See More

52-Week High 163.71
Fibonacci 61.8% 129.12
Last Price 120.24
Fibonacci 50% 118.44
Fibonacci 38.2% 107.75
52-Week Low 73.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar